Oragenics (LTS:0A64) Short Interest


LTS:0A64 Oragenics Inc LTS:0A64
30 GF Score
Price $5.13
! 1 Warning Sign
View Full Analysis

What is Oragenics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0A64 vs ITRMF, CASIF, AZTR: Short Interest Comparison

For the Biotechnology subindustry, Oragenics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oragenics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Short Interest distribution charts can be found below:

* The bar in red indicates where Oragenics's Short Interest falls into.


LTS:0A64
30GF Score
Oragenics Inc LTS:0A64
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oragenics Business Description

Other Exchanges OGEN:USA
Address 9015 Town Center Parkway, Suite 143, Lakewood Ranch, FL, USA, 34202
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
30GF Score

Get the complete analysis for LTS:0A64

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.13
Price